Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2322277 | 0.91 | KDM4E (0.63) | KDM4EALDH1A1SMN1; SMN2HRH3POLB | |
| SCHEMBL7564110 | 0.87 | KDM4E (0.82) | KDM4EALDH1A1SMN1; SMN2HRH3ACHE | |
| SCHEMBL3573539 | 0.83 | HRH3 (0.59) | KDM4EALDH1A1HRH3ATML3MBTL1 | |
| SCHEMBL30735248 | 0.83 | KDM4E (0.62) | KDM4EALDH1A1HRH3ATML3MBTL1 | |
| SCHEMBL14970474 | 0.82 | KDM4E (0.75) | KDM4EALDH1A1SMN1; SMN2HRH3POLB | |
| SCHEMBL7399802 | 0.81 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2HRH3POLB | |
| SCHEMBL7396432 | 0.81 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2HRH3POLB | |
| SCHEMBL7398924 | 0.81 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2HRH3POLB | |
| SCHEMBL1776035 | 0.81 | HRH3 (0.62) | KDM4EALDH1A1HRH3ATML3MBTL1 | |
| Hydrochloric Acid SCHEMBL7594910 | 0.80 | KDM4E (0.71) | KDM4EALDH1A1SMN1; SMN2HRH3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| EP-1567511-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004035556-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | HRH3, HRH4, HRH2 | KDM4E 393/4885ALDH1A1 1903/4885SMN1; SMN2 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.